<DOC>
	<DOCNO>NCT03066635</DOCNO>
	<brief_summary>Cluster headache ( CH ) common trigeminal autonomic cephalalgia one severe pain known man , large impact sufferer 's quality life . A parasympathetic dysfunction CH suggest . The sphenopalatine ganglion target treatment primary headache disorder century several anatomic physiologic study suggest another cranial parasympathetic ganglion , otic ganglion ( OG ) , might also relevant CH . In study OG block botulinum toxin type A pilot study 10 patient chronic cluster headache . Recruitment patient solely Norway . There data available determine correct dosage botulinum toxin . A similar neural structure block botulinum toxin human sphenopalatine ganglion . The investigator inject 10 patient suffer intractable chronic cluster headache botulinum toxin sphenopalatine ganglion . 5 patient give 25 IU 5 patient give 50 IU . Even though number treat patient low , appear difference adverse event profile receive 25 Iu receive 50 IU . The investigator also previously inject 25 IU botulinum toxin towards sphenopalatine ganglion bilaterally ( i.e . 25 IU side ) 10 patient suffer intractable chronic migraine . Doses 25 IU inject structure adjacent otic ganglion , instance dystonia towards lateral pterygoid muscle . Thus decide study injection towards otic ganglion , explore safety 12.5 25 IU botulinum toxin .</brief_summary>
	<brief_title>Botulinum Toxin Type A Block Otic Ganglion Chronic Cluster Headache : Safety Issues</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Ganglion Cysts</mesh_term>
	<mesh_term>Synovial Cyst</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Informed write consent Fulfilling International Classification Headache Disorders ( ICHD ) 3 Beta criterion chronic cluster headache Mean attack frequency four attack per week Agreeing refrain start new prophylactic cluster headache medication , include steroid , therapy aim cluster headache , agree maintain exist prophylactic cluster headache medication 4 week enter baseline period throughout duration study Intractable cluster headache , i.e . unsatisfactory effect , intolerable side effect contraindication least 2 follow medication : Verapamil , Lithium , Suboccipital steroid injection , Able distinguish cluster headache attack type headache . Modification addition prophylactic drug dose use cluster headache last 4 week inclusion trial Use antipsychotic medication last 4 week inclusion Concomitant significant heart lung disease Systemic local condition increase risk procedure Psychiatric psychological condition interfere participation study Pregnancy Breast feed Inadequate use contraceptive Opioid overuse Abuse drug include alcohol Anatomical variant might impede study treatment Known hypersensitivity botulinum toxin type A excipients find Botox Current treatment drug interact botulinum toxin : aminoglycosides , spectinomycin , neuromuscular blocker , depolarize agent ( succinylcholine ) nondepolarizing agent ( tubocurarine derivates ) , lincosamides , polymyxin , quinidine , magnesium sulfate anticholinesterase . Previous cerebral ischemic infarction Not able take magnetic resonance imaging ( MRI ) Previous destructive surgery interventional procedure involve C2 C3 root ( vertebra ) , sphenopalatine ganglion , extracranial nerve , trigeminal nerve , deep brain stimulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nerve block</keyword>
	<keyword>Ganglia , Parasympathetic</keyword>
	<keyword>Botulinum Toxins , Type A</keyword>
	<keyword>Injection</keyword>
</DOC>